WEBULL

Is MediPal Holdings (TSE:7459) Still Worth A Look On Higher Dividend Guidance?

Simply Wall St · 2d ago

MediPal Holdings (TSE:7459) has updated investors with higher full year dividend guidance and revised earnings expectations after completing its tender offer for PALTAC Corporation, which shifts more of PALTAC's profit fully onto its books.

See our latest analysis for MediPal Holdings.

Recent moves suggest growing interest in MediPal Holdings, with a 1 month share price return of 9.92% and a 1 year total shareholder return of 19.90%. This points to building momentum around the revised earnings and dividend guidance.

If this kind of earnings and dividend story has your attention, it could be a good moment to broaden your search and check out 11 top founder-led companies

MediPal Holdings now looks like a larger, more dividend focused business after the PALTAC deal, but the share price has already moved. Is the stock still offering good value at today’s level?

Price to Earnings of 13.7x: Is it justified?

MediPal Holdings is currently trading on a P/E of 13.7x, which suggests the market is placing a moderate earnings multiple on the stock at the last close of ¥2,848.5.

The P/E multiple compares the share price to earnings per share and is often used for established businesses with consistent profits, such as healthcare distributors. For MediPal Holdings, this ratio helps indicate how much investors are paying for each unit of current earnings.

While the stock is described as expensive versus its peer average P/E of 12.6x, it is also flagged as good value against an estimated fair P/E of 17.4x. That contrast suggests the current market price could be sitting between what peers trade on today and where the SWS fair ratio model indicates the multiple could move if the company were priced in line with its fundamentals.

Relative to the broader JP Healthcare industry, MediPal Holdings is trading in line with the sector P/E average of 13.7x. This implies the market is valuing its earnings similarly to other healthcare stocks rather than assigning a premium or discount based purely on sector comparison. The gap between the current 13.7x and the higher fair P/E estimate is where the potential valuation re rating case sits.

Explore the SWS fair ratio for MediPal Holdings

Result: Price-to-Earnings of 13.7x (UNDERVALUED)

However, MediPal Holdings still faces risks around integrating PALTAC smoothly and maintaining its current dividend guidance if earnings or wholesale demand soften from here.

Find out about the key risks to this MediPal Holdings narrative.

Another View: MediPal Holdings Through a DCF Lens

While the P/E of 13.7x suggests MediPal Holdings is reasonably priced against peers, the SWS DCF model presents a different perspective. At a share price of ¥2,848.5 versus an estimated future cash flow value of ¥6,554.6, the stock appears significantly undervalued. Which signal should be more important for you at this time?

For a closer look at how this cash flow based estimate is built, take a moment to review the Look into how the SWS DCF model arrives at its fair value.

7459 Discounted Cash Flow as at Jul 2026
7459 Discounted Cash Flow as at Jul 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out MediPal Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 18 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of dividend upgrades and valuation signals around MediPal Holdings feels encouraging, consider testing the numbers yourself and weighing the optimism against the detailed 4 key rewards.

Looking for more investment ideas beyond MediPal Holdings?

If MediPal Holdings has sharpened your focus, do not stop here, use the Simply Wall St screener to uncover more stocks that fit what you are looking for.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.